Abstract: Objective To investigate the relationship between BRAFV600E mutation in PTC and the expression of various molecular markers and the clinicopathological characteristics of the tumor. Predict that BRAFV600E mutation is an indicator of poor prognosis. Methods The BRAFV600E mutation was detected by real-time PCR, and the expressions of galectin-3, cyclin D1, VEGF and MMP-9 were detected by immunohistochemistry. Results Of 104 PTC patients, 71 cases (68.3%) were BRAFV600E mutation (+). These cases had significantly larger sizes, higher tumor T stage, were more likely to invade the thyroid epithelium and lymph node metastasis, and the expression of VEGF and MMP-9 was up-regulated(P＜0.05). Binary Logist regression analysis showed that ，the cases with BRAFV600E mutation (+) had significantly higher expression of VEGF protein, larger tumor diameter, and higher T stage of the tumor, more likely to invade the thyroid epithelial tissue(P＜0.05). Conclusions PTC with BRAFV600E mutation has a higher invasive and metastatic potential.

Key words: Papillary thyroid carcinoma，BRAFV600E mutation，Vascular endothelial growth factor，Matrix metalloproteinase-9